Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors.

Deaton DN, Do Y, Holt J, Jeune MR, Kramer HF, Larkin AL, Orband-Miller LA, Peckham GE, Poole C, Price DJ, Schaller LT, Shen Y, Shewchuk LM, Stewart EL, Stuart JD, Thomson SA, Ward P, Wilson JW, Xu T, Guss JH, Musetti C, Rendina AR, Affleck K, Anders D, Hancock AP, Hobbs H, Hodgson ST, Hutchinson J, Leveridge MV, Nicholls H, Smith IED, Somers DO, Sneddon HF, Uddin S, Cleasby A, Mortenson PN, Richardson C, Saxty G.

Bioorg Med Chem. 2019 Apr 15;27(8):1456-1478. doi: 10.1016/j.bmc.2019.02.017. Epub 2019 Feb 11.

PMID:
30858025
2.

Charge Separation and Triplet Exciton Formation Pathways in Small Molecule Solar Cells as Studied by Time-resolved EPR Spectroscopy.

Thomson SAJ, Niklas J, Mardis KL, Mallares C, Samuel IDW, Poluektov OG.

J Phys Chem C Nanomater Interfaces. 2017 Oct 19;121(41):22707-22719. doi: 10.1021/acs.jpcc.7b08217. Epub 2017 Sep 13.

3.

Taxonomy based on science is necessary for global conservation.

Thomson SA, Pyle RL, Ahyong ST, Alonso-Zarazaga M, Ammirati J, Araya JF, Ascher JS, Audisio TL, Azevedo-Santos VM, Bailly N, Baker WJ, Balke M, Barclay MVL, Barrett RL, Benine RC, Bickerstaff JRM, Bouchard P, Bour R, Bourgoin T, Boyko CB, Breure ASH, Brothers DJ, Byng JW, Campbell D, Ceríaco LMP, Cernák I, Cerretti P, Chang CH, Cho S, Copus JM, Costello MJ, Cseh A, Csuzdi C, Culham A, D'Elía G, d'Udekem d'Acoz C, Daneliya ME, Dekker R, Dickinson EC, Dickinson TA, van Dijk PP, Dijkstra KB, Dima B, Dmitriev DA, Duistermaat L, Dumbacher JP, Eiserhardt WL, Ekrem T, Evenhuis NL, Faille A, Fernández-Triana JL, Fiesler E, Fishbein M, Fordham BG, Freitas AVL, Friol NR, Fritz U, Frøslev T, Funk VA, Gaimari SD, Garbino GST, Garraffoni ARS, Geml J, Gill AC, Gray A, Grazziotin FG, Greenslade P, Gutiérrez EE, Harvey MS, Hazevoet CJ, He K, He X, Helfer S, Helgen KM, van Heteren AH, Hita Garcia F, Holstein N, Horváth MK, Hovenkamp PH, Hwang WS, Hyvönen J, Islam MB, Iverson JB, Ivie MA, Jaafar Z, Jackson MD, Jayat JP, Johnson NF, Kaiser H, Klitgård BB, Knapp DG, Kojima JI, Kõljalg U, Kontschán J, Krell FT, Krisai-Greilhuber I, Kullander S, Latella L, Lattke JE, Lencioni V, Lewis GP, Lhano MG, Lujan NK, Luksenburg JA, Mariaux J, Marinho-Filho J, Marshall CJ, Mate JF, McDonough MM, Michel E, Miranda VFO, Mitroiu MD, Molinari J, Monks S, Moore AJ, Moratelli R, Murányi D, Nakano T, Nikolaeva S, Noyes J, Ohl M, Oleas NH, Orrell T, Páll-Gergely B, Pape T, Papp V, Parenti LR, Patterson D, Pavlinov IY, Pine RH, Poczai P, Prado J, Prathapan D, Rabeler RK, Randall JE, Rheindt FE, Rhodin AGJ, Rodríguez SM, Rogers DC, Roque FO, Rowe KC, Ruedas LA, Salazar-Bravo J, Salvador RB, Sangster G, Sarmiento CE, Schigel DS, Schmidt S, Schueler FW, Segers H, Snow N, Souza-Dias PGB, Stals R, Stenroos S, Stone RD, Sturm CF, Štys P, Teta P, Thomas DC, Timm RM, Tindall BJ, Todd JA, Triebel D, Valdecasas AG, Vizzini A, Vorontsova MS, de Vos JM, Wagner P, Watling L, Weakley A, Welter-Schultes F, Whitmore D, Wilding N, Will K, Williams J, Wilson K, Winston JE, Wüster W, Yanega D, Yeates DK, Zaher H, Zhang G, Zhang ZQ, Zhou HZ.

PLoS Biol. 2018 Mar 14;16(3):e2005075. doi: 10.1371/journal.pbio.2005075. eCollection 2018 Mar. No abstract available.

4.

Characterization of selective Calcium-Release Activated Calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparations.

Rice LV, Bax HJ, Russell LJ, Barrett VJ, Walton SE, Deakin AM, Thomson SA, Lucas F, Solari R, House D, Begg M.

Eur J Pharmacol. 2013 Mar 15;704(1-3):49-57. doi: 10.1016/j.ejphar.2013.02.022. Epub 2013 Feb 27.

PMID:
23454522
5.

Oligothiophene cruciform with a germanium spiro center: a promising material for organic photovoltaics.

Wright IA, Kanibolotsky AL, Cameron J, Tuttle T, Skabara PJ, Coles SJ, Howells CT, Thomson SA, Gambino S, Samuel ID.

Angew Chem Int Ed Engl. 2012 May 7;51(19):4562-7. doi: 10.1002/anie.201109074. Epub 2012 Mar 30. No abstract available.

PMID:
22473752
6.

Using WHO-FRAX to describe fracture risk: experience in primary care.

MacLean FR, Thomson SA, Gallacher SJ.

Scott Med J. 2012 Feb;57(1):8-13. doi: 10.1258/smj.2011.011185. Epub 2011 Dec 16.

PMID:
22179858
7.

Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis.

West NP, Thomson SA, Triccas JA, Medveczky CJ, Ramshaw IA, Britton WJ.

Vaccine. 2011 Oct 13;29(44):7759-65. doi: 10.1016/j.vaccine.2011.07.109. Epub 2011 Aug 16.

PMID:
21846485
8.

Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism.

Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D, Chu SH, Moreau MP, Gupta AR, Thomson SA, Mason CE, Bilguvar K, Celestino-Soper PB, Choi M, Crawford EL, Davis L, Wright NR, Dhodapkar RM, DiCola M, DiLullo NM, Fernandez TV, Fielding-Singh V, Fishman DO, Frahm S, Garagaloyan R, Goh GS, Kammela S, Klei L, Lowe JK, Lund SC, McGrew AD, Meyer KA, Moffat WJ, Murdoch JD, O'Roak BJ, Ober GT, Pottenger RS, Raubeson MJ, Song Y, Wang Q, Yaspan BL, Yu TW, Yurkiewicz IR, Beaudet AL, Cantor RM, Curland M, Grice DE, Günel M, Lifton RP, Mane SM, Martin DM, Shaw CA, Sheldon M, Tischfield JA, Walsh CA, Morrow EM, Ledbetter DH, Fombonne E, Lord C, Martin CL, Brooks AI, Sutcliffe JS, Cook EH Jr, Geschwind D, Roeder K, Devlin B, State MW.

Neuron. 2011 Jun 9;70(5):863-85. doi: 10.1016/j.neuron.2011.05.002.

9.

Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2.

Haffner CD, Thomson SA, Guo Y, Petrov K, Larkin A, Banker P, Schaaf G, Dickerson S, Gobel J, Gillie D, Condreay JP, Poole C, Carpenter T, Ulrich J.

Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92. doi: 10.1016/j.bmcl.2010.09.131. Epub 2010 Oct 23.

PMID:
20974533
10.

N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 inhibitors. Part 1.

Haffner CD, Thomson SA, Guo Y, Schaller LT, Boggs S, Dickerson S, Gobel J, Gillie D, Condreay JP.

Bioorg Med Chem Lett. 2010 Dec 1;20(23):6983-8. doi: 10.1016/j.bmcl.2010.09.132. Epub 2010 Oct 7.

PMID:
20971642
11.

Annotation, phylogenetics, and expression of the nuclear receptors in Daphnia pulex.

Thomson SA, Baldwin WS, Wang YH, Kwon G, Leblanc GA.

BMC Genomics. 2009 Oct 28;10:500. doi: 10.1186/1471-2164-10-500.

12.

Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine.

Lutzky VP, Corban M, Heslop L, Morrison LE, Crooks P, Hall DF, Coman WB, Thomson SA, Moss DJ.

J Virol. 2010 Jan;84(1):407-17. doi: 10.1128/JVI.01303-09.

13.

De novo sequencing of RCB-1 to -3: peptide biomarkers from the castor bean plant Ricinus communis.

Ovenden SP, Fredriksson SA, Bagas CK, Bergström T, Thomson SA, Nilsson C, Bourne DJ.

Anal Chem. 2009 May 15;81(10):3986-96. doi: 10.1021/ac900371y.

PMID:
19391602
14.

Minitablets: new modality to deliver medicines to preschool-aged children.

Thomson SA, Tuleu C, Wong IC, Keady S, Pitt KG, Sutcliffe AG.

Pediatrics. 2009 Feb;123(2):e235-8. doi: 10.1542/peds.2008-2059.

PMID:
19171575
15.

Time-dependent inactivation of human phenylethanolamine N-methyltransferase by 7-isothiocyanatotetrahydroisoquinoline.

Wu Q, Caine JM, Thomson SA, Slavica M, Grunewald GL, McLeish MJ.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1071-4. doi: 10.1016/j.bmcl.2009.01.014. Epub 2009 Jan 10.

16.

Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.

Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1177-82. doi: 10.1016/j.bmcl.2008.12.085. Epub 2008 Dec 25.

PMID:
19138846
17.

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.

Sparks SM, Banker P, Bickett DM, Clancy DC, Dickerson SH, Garrido DM, Golden PL, Peat AJ, Sheckler LR, Tavares FX, Thomson SA, Weiel JE.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):981-5. doi: 10.1016/j.bmcl.2008.11.084. Epub 2008 Nov 27.

PMID:
19095443
18.

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.

Sparks SM, Banker P, Bickett DM, Carter HL, Clancy DC, Dickerson SH, Dwornik KA, Garrido DM, Golden PL, Nolte RT, Peat AJ, Sheckler LR, Tavares FX, Thomson SA, Wang L, Weiel JE.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):976-80. doi: 10.1016/j.bmcl.2008.11.085. Epub 2008 Nov 27.

PMID:
19095442
19.

Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitors.

Evans KA, Li YH, Coppo FT, Graybill TL, Cichy-Knight M, Patel M, Gale J, Li H, Thrall SH, Tew D, Tavares F, Thomson SA, Weiel JE, Boucheron JA, Clancy DC, Epperly AH, Golden PL.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4068-71. doi: 10.1016/j.bmcl.2008.05.102. Epub 2008 Jun 12.

PMID:
18554908
20.

Validation and application of a GC-MS method for determining soman concentration in rat plasma following low-level vapor exposure.

Renner JA, Dabisch PA, Evans RA, McGuire JM, Totura AL, Jakubowski EM, Thomson SA.

J Anal Toxicol. 2008 Jan-Feb;32(1):92-8.

PMID:
18269800
21.

Quantification of sarin and cyclosarin metabolites isopropyl methylphosphonic acid and cyclohexyl methylphosphonic acid in minipig plasma using isotope-dilution and liquid chromatography- time-of-flight mass spectrometry.

Evans RA, Jakubowski EM, Muse WT, Matson K, Hulet SW, Mioduszewski RJ, Thomson SA, Totura AL, Renner JA, Crouse CL.

J Anal Toxicol. 2008 Jan-Feb;32(1):78-85.

PMID:
18269798
22.

Quantification of nerve agent VX-butyrylcholinesterase adduct biomarker from an accidental exposure.

Solano MI, Thomas JD, Taylor JT, McGuire JM, Jakubowski EM, Thomson SA, Maggio VL, Holland KE, Smith JR, Capacio B, Woolfitt AR, Ashley DL, Barr JR.

J Anal Toxicol. 2008 Jan-Feb;32(1):68-72.

PMID:
18269796
23.

A rapid and sensitive technique for assessing exposure to VX via GC-MS-MS analysis.

McGuire JM, Byers CE, Hulet SW, Jakubowski EM, Thomson SA.

J Anal Toxicol. 2008 Jan-Feb;32(1):63-7.

PMID:
18269795
24.

Gas chromatography-tandem mass spectrometry analysis of red blood cells from Göttingen minipig following whole-body vapor exposure to VX.

Byers CE, McGuire JM, Hulet SW, Burnett DC, Gaviola BI, Jakubowski EM, Thomson SA.

J Anal Toxicol. 2008 Jan-Feb;32(1):57-62.

PMID:
18269794
25.

Biomarkers of low-level exposure to soman vapor: comparison of fluoride regeneration to acetylcholinesterase inhibition.

Dabisch PA, Davis EA, Renner JA, Jakubowski EM, Mioduszewski RJ, Thomson SA.

Inhal Toxicol. 2008 Jan;20(2):149-56. doi: 10.1080/08958370701821300 .

PMID:
18236229
26.

An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation.

Perrin GQ, Li H, Fishbein L, Thomson SA, Hwang MS, Scarborough MT, Yachnis AT, Wallace MR, Mareci TH, Muir D.

Lab Invest. 2007 Nov;87(11):1092-102. Epub 2007 Sep 17.

27.

Kinetics of sarin (GB) following a single sublethal inhalation exposure in the guinea pig.

Whalley CE, McGuire JM, Miller DB, Jakubowski EM, Mioduszewski RJ, Thomson SA, Lumley LA, McDonough JH, Shih TM.

Inhal Toxicol. 2007 Jun;19(8):667-81.

PMID:
17510839
28.

Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line.

Perrin GQ, Fishbein L, Thomson SA, Thomas SL, Stephens K, Garbern JY, DeVries GH, Yachnis AT, Wallace MR, Muir D.

J Neurosci Res. 2007 May 1;85(6):1347-57.

PMID:
17335073
29.

Effects of whole-body VX vapor exposure on lethality in rats.

Benton BJ, McGuire JM, Sommerville DR, Dabisch PA, Jakubowski EM, Matson KL, Mioduszewski RJ, Thomson SA, Crouse CL.

Inhal Toxicol. 2006 Dec;18(14):1091-9.

PMID:
17050346
30.

Synthesis and structure-activity relationships of 3-phenyl-2-propenamides as inhibitors of glycogen phosphorylase a.

Li YH, Coppo FT, Evans KA, Graybill TL, Patel M, Gale J, Li H, Tavares F, Thomson SA.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5892-6. Epub 2006 Aug 30.

PMID:
16942879
31.

Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3.

Smalley TL Jr, Peat AJ, Boucheron JA, Dickerson S, Garrido D, Preugschat F, Schweiker SL, Thomson SA, Wang TY.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2091-4. Epub 2006 Feb 7.

PMID:
16460937
32.

Comparison of low-level sarin and cyclosarin vapor exposure on pupil size of the Gottingen minipig: effects of exposure concentration and duration.

Hulet SW, Sommerville DR, Crosier RB, Dabisch PA, Miller DB, Benton BJ, Forster JS, Scotto JA, Jarvis JR, Krauthauser C, Muse WT, Reutter SA, Mioduszewski RJ, Thomson SA.

Inhal Toxicol. 2006 Feb;18(2):143-53.

PMID:
16393929
33.

Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials.

Coupar BE, Purcell DF, Thomson SA, Ramshaw IA, Kent SJ, Boyle DB.

Vaccine. 2006 Feb 27;24(9):1378-88. Epub 2005 Oct 5.

PMID:
16257479
34.

Microarray analysis of differentially expressed genes of primary tumors in the canine central nervous system.

Thomson SA, Kennerly E, Olby N, Mickelson JR, Hoffmann DE, Dickinson PJ, Gibson G, Breen M.

Vet Pathol. 2005 Sep;42(5):550-8.

PMID:
16145201
35.

Tolerance to the miotic effect of sarin vapor in rats after multiple low-level exposures.

Dabisch PA, Burnett DC, Miller DB, Jakubowski EM, Muse WT, Forster JS, Scotto JA, Jarvis JR, Davis EA, Hulet SW, Reutter SA, Mioduszewski RJ, Thomson SA.

J Ocul Pharmacol Ther. 2005 Jun;21(3):182-95.

PMID:
15969635
36.

Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.

Thomson SA, Jaramillo AB, Shoobridge M, Dunstan KJ, Everett B, Ranasinghe C, Kent SJ, Gao K, Medveckzy J, Ffrench RA, Ramshaw IA.

Vaccine. 2005 Sep 7;23(38):4647-57.

PMID:
15964105
37.

Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier.

Hildyard JC, Ammälä C, Dukes ID, Thomson SA, Halestrap AP.

Biochim Biophys Acta. 2005 Apr-May;1707(2-3):221-30. Epub 2004 Dec 30.

38.

Miotic tolerance to sarin vapor exposure: role of the sympathetic and parasympathetic nervous systems.

Dabisch PA, Miller DB, Reutter SA, Mioduszewski RJ, Thomson SA.

Toxicol Sci. 2005 Jun;85(2):1041-7. Epub 2005 Mar 23.

PMID:
15788726
39.

N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.

Tavares FX, Boucheron JA, Dickerson SH, Griffin RJ, Preugschat F, Thomson SA, Wang TY, Zhou HQ.

J Med Chem. 2004 Sep 9;47(19):4716-30.

PMID:
15341487
40.

Quantitation of fluoride ion released sarin in red blood cell samples by gas chromatography-chemical ionization mass spectrometry using isotope dilution and large-volume injection.

Jakubowski EM, McGuire JM, Evans RA, Edwards JL, Hulet SW, Benton BJ, Forster JS, Burnett DC, Muse WT, Matson K, Crouse CL, Mioduszewski RJ, Thomson SA.

J Anal Toxicol. 2004 Jul-Aug;28(5):357-63.

PMID:
15239856
41.

Novel GSK-3 inhibitors with improved cellular activity.

Peat AJ, Garrido D, Boucheron JA, Schweiker SL, Dickerson SH, Wilson JR, Wang TY, Thomson SA.

Bioorg Med Chem Lett. 2004 May 3;14(9):2127-30.

PMID:
15080993
42.

Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors.

Peat AJ, Boucheron JA, Dickerson SH, Garrido D, Mills W, Peckham J, Preugschat F, Smalley T, Schweiker SL, Wilson JR, Wang TY, Zhou HQ, Thomson SA.

Bioorg Med Chem Lett. 2004 May 3;14(9):2121-5.

PMID:
15080992
43.

A recombinant vaccinia virus encoding the interferon-inducible T-cell alpha chemoattractant is attenuated in vivo.

Hamilton NH, Mahalingam S, Banyer JL, Ramshaw IA, Thomson SA.

Scand J Immunol. 2004 Mar;59(3):246-54.

44.

QSAR studies on P-glycoprotein-regulated multidrug resistance and on its reversal by phenothiazines.

Dearden JC, Al-Noobi A, Scott AC, Thomson SA.

SAR QSAR Environ Res. 2003 Oct-Dec;14(5-6):447-54.

PMID:
14758987
45.

3-trifluoromethyl-4-nitro-5-arylpyrazoles are novel K(ATP) channel agonists.

Peat AJ, Townsend C, Craig McKay M, Garrido D, Terry CM, Wilson JL, Thomson SA.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):813-6.

PMID:
14741296
46.

Combinations of IFN-gamma and IL-4 induce distinct profiles of dendritic cell-associated immunoregulatory properties.

Banyer JL, Halliday DC, Thomson SA, Hamilton NH.

Genes Immun. 2003 Sep;4(6):427-40.

PMID:
12944980
47.

Formation of Hirano bodies induced by expression of an actin cross-linking protein with a gain-of-function mutation.

Maselli A, Furukawa R, Thomson SA, Davis RC, Fechheimer M.

Eukaryot Cell. 2003 Aug;2(4):778-87.

48.

Calcium regulation of actin crosslinking is important for function of the actin cytoskeleton in Dictyostelium.

Furukawa R, Maselli A, Thomson SA, Lim RW, Stokes JV, Fechheimer M.

J Cell Sci. 2003 Jan 1;116(Pt 1):187-96.

49.

NF1 mutations and molecular testing.

Thomson SA, Fishbein L, Wallace MR.

J Child Neurol. 2002 Aug;17(8):555-61; discussion 571-2, 646-51. Review.

PMID:
12403553
50.

Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives as K(ATP) channel agonists.

Peat AJ, Townsend C, Worley JF 3rd, Allen SH, Garrido D, Mertz RJ, Pfohl JL, Terry CM, Truax JF, Veasey RL, Thomson SA.

Bioorg Med Chem Lett. 2002 Oct 21;12(20):2977-80.

PMID:
12270187

Supplemental Content

Loading ...
Support Center